Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

122

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Childhood Anaplastic Large Cell Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Neuroblastoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Neuroblastoma

Interventions

DRUG: Crizotinib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
OTHER: Questionnaire Administration

Sponsor

Children's Oncology Group

Collaborators

[object Object]
[object Object]